Notice of the 37th Annual General Meeting (AGM) of the Company

CSD/BSE&NSE/AGM Notice 2025-26 Date: July 30, 2026 To To Listing Department Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Notice of 37th Annual General Meeting (AGM) Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith Notice of the 37th Annual General Meeting of the Company, scheduled to be held on Tuesday, August 25, 2026 at 11:30 a.m. (IST) through Video Conference (VC) / Other Audio Visual Means (OAVM). The Annual Report containing Notice of the AGM is available at: http://www.suven.com/annualreports.aspx The schedule of the remote e-voting is set out below: Cut-off date for e-voting Tuesday, August 18, 2026 E-voting start date and time Friday, August 21, 2026 at 9:00 a.m. IST E-voting end date and time Monday, August 24, 2026 at 5:00 p.m. IST This is for your information and record. Thanking you. For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary Encl.: As above Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 3311/ 3315 Email: info@suven.com website: www.suven.com SUVEN LIFE SCIENCES LIMITED Notice of Annual General Meeting NOTICE IS HEREBY GIVEN THAT THE 37TH ANNUAL GENERAL MEETING OF THE MEMBERS OF SUVEN LIFE SCIENCES LIMITED WILL BE HELD ON TUESDAY, 25TH DAY OF AUGUST, 2026, AT 11:30 A.M. IST THROUGH VIDEO CONFERENCING (”VC”) / OTHER AUDIO-VISUAL MEANS (“OAVM”) TO TRANSACT THE FOLLOWING BUSINESSES: ORDINARY BUSINESS Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), read with SEBI Master Circular No. HO/CFD/PoD2/CIR/P/2026/ dated ITEM NO. 1: Adoption of Financial Statements January 30, 2026 (as amended from time to time), and the Policy To receive, consider and adopt the audited standalone and on Related Party Transactions of the Company, and pursuant consolidated financial statements of the Company for the to the prior approval of the Audit Committee and the Board of financial year ended March 31, 2026 together with the Reports Directors, the approval of the Members of the Company be and of the Board of Directors and the Auditor’s thereon and in this is hereby accorded for the appointment of Dr. Madhavi Jasti, regard, to consider and if thought fit, to pass, with or without MD, daughter of Mr. Venkateswarlu Jasti (Chairman & Managing modification(s), the following resolution as an Ordinary Director) and Mrs. Sudha Rani Jasti (Whole-time Director), to hold Resolution: an office or place of profit for overseeing and managing medical “RESOLVED THAT the audited standalone and consolidated affairs, regulatory coordination, and medical monitoring of all financial statements of the Company for the financial year clinical development activities of the Company’s Wholly Owned ended March 31, 2026 together with the Reports of the Board Subsidiaries in the United States of America and Singapore with of Directors and the Auditor’s thereon, as circulated to the effect from 1st September, 2026, on such terms and conditions, Members, be and are hereby considered and adopted.” as may be mutually agreed between Dr. Madhavi Jasti and the Wholly Owned Subsidiaries, in compliance with applicable laws/ ITEM NO. 2: To appoint Prof. Seyed E Hasnain (DIN: regulations.” 02205199), as a Director liable to retire by rotation: “RESOLVED FURTHER THAT Dr. Madhavi Jasti shall be paid an To appoint a Director in place of Prof. Seyed E Hasnain (DIN: aggregate remuneration of USD 400,000 per annum initially, 02205199) who retires by rotation, and being eligible, offers which may be revised from time to time in accordance with himself for re-appointment. the terms of contract of engagement, subject to an aggregate To consider and, if thought fit, to pass with or without maximum remuneration of USD 1,000,000 per annum; and modification, the following resolution as an Ordinary that such aggregate remuneration shall be borne and paid, in Resolution: whole or in part, by either or both of the Company’s Wholly Owned Subsidiaries from time to time in USD outside India, “RESOLVED THAT pursuant to the provisions of Section 152 of having regard to their respective business requirements and the Companies Act, 2013 and other applicable provisions of the the services rendered by her.” Companies Act, 2013, Prof. Seyed E Hasnain (DIN: 02205199) who retire by rotation at this meeting and being eligible has offered “RESOLVED FURTHER THAT the Board of Directors of the himself for re-appointment, be and is hereby re-appointed as a Company (including any Committee thereof) be and is hereby Director of the Company, liable to retire by rotation.” authorised to do all such acts, deeds, matters and things as may be necessary, proper or expedient to give effect to this SPECIAL BUSINESS: resolution, including but not limited to making necessary ITEM No 3. To Approve the Related Party Transaction disclosures, if any, to the statutory authorities under applicable relating to the Appointment of Dr. Madhavi Jasti, MD, Laws and Regulations of SEBI LODR, periodic reporting to the to an Office or Place of Profit in Overseas Wholly Owned Audit Committee and the Board, and to settle any question, Subsidiaries of the Company difficulty or doubt that may arise in this regard.” To consider and if taught fit, to pass with or without modification, “RESOLVED FURTHER THAT the Board, be and is hereby the following resolution as an Ordinary Resolution authorised to delegate all or any of the powers herein conferred, to any Director(s) or Chief Financial Officer or Company “RESOLVED THAT pursuant to the provisions of Section 188(1) Secretary or any other Officer(s), Authorised Representative(s) (f) and other applicable provisions, if any, of the Companies Act, of the Company, to do all such acts and take such steps, as may 2013 (“the Act”) read with Rule 15(3) of the Companies (Meetings be considered necessary or expedient, to give effect to the of Board and its Powers) Rules, 2014, and in accordance with aforesaid resolution(s).” Regulation 2(1)(zb), Regulation 2(1)(zc), Regulation 23 (4) and other applicable provisions of the SEBI (Listing Obligations and ANNUAL REPORT 2025-26 NOTICE ITEM No. 4: To re-appoint Dr. Vajja Sambasiva Rao (DIN: ITEM No 5: To approve the variation in the utilisation of 09233939) as an Independent Director of the Company. funds raised through Preferential Issue To consider and if thought fit, to pass with or without To consider and if taught fit, to pass with or without modification, modification, the following resolution as Special Resolution the following resolution as Special Resolution “RESOLVED THAT pursuant to the provisions of Sections 149, “RESOLVED THAT pursuant to the applicable provisions, if any, 150 and 152 read with Schedule IV and all other applicable of the Companies Act, 2013, the Securities and Exchange Board provisions, if any, of the Companies Act, 2013 (“Act”) and the of India (Listing Obligations and Disclosure Requirements) rules made thereunder, including the Companies (Appointment Regulations, 2015, the Securities and Exchange Board of India and Qualification of Directors) Rules, 2014, as amended from (Issue of Capital and Disclosure Requirements) Regulations, time to time, and Regulation 17, 17(1A), 25 and other applicable 2018, and other applicable laws, rules, regulations, circulars, provisions of the Securities and Exchange Board of India (Listing notifications and statutory modifications or re-enactments Obligations and Disclosure Requirements) Regulations, 2015 thereof for the time being in force, and pursuant to the (“SEBI Listing Regulations”), as amended from time to time, and r [Showing first 8,000 characters — download PDF for full document]